和血明目片和康柏西普联合激光光凝治疗重度增殖性糖尿病性视网膜病变的疗效  

Observation on Therapeutic Effect to Treat Severe PDR Jointly with Hexuemingmu Tablet, Conbercept and Retinal Photocoagulation

作　　者：刘彩金 张俊霞[1] 白雪[1] LIU Caijin;ZHANG Junxia;BAI Xue(Department of Ophthalmology,Yan'an People's Hospital,Yan'an 716000,China)

机构地区：[1]延安市人民医院眼科,延安市716000

出　　处：《中国激光医学杂志》2022年第5期276-280,300,共6页Chinese Journal of Laser Medicine & Surgery

摘　　要：目的 观察和血明目片与康柏西普联合激光光凝治疗重度增殖性糖尿病性视网膜病变(proliferative diabetic retinopathy,PDR)的临床效果。方法 选取2018年6月至2019年8月,PDR患者120例216只眼,随机分为对照组和观察组,每组患者各60例。对照组给予康柏西普联合激光光凝治疗,康柏西普注射治疗前1周行激光光凝治疗,激光参数设置:曝光时间100~150 ms,功率为100~180 mW,光凝强度为Ⅰ~Ⅱ级,光斑大小为100μm,光斑之间间隔约为1个光斑大小;观察组在对照组治疗的基础上给予和血明目片治疗,比较两组患者的治疗后1个月、2个月和3个月内的最佳矫正视力改变、记录视网膜渗出改善情况以判定临床疗效,及黄斑中心凹厚度和不良反应发生率。结果 观察组患者治疗后最佳矫正视力显著高于对照组(P<0.05);治疗后,两组患者的临床疗效与黄斑中心凹厚度与治疗前比较均有改善,其中观察组的临床疗效和黄斑中心凹厚度较对照组改善更显著(P<0.05);治疗后,两组患者均未发生眼内炎、术后出血、视网膜脱离等不良反应。结论 和血明目片与康柏西普联合视网膜光凝治疗重度PDR可提高患者视功能,促进患者恢复,临床效果显著。Objective To observe the clinical efficacy to use Hexuemingmu tablet,Conbercept and retinal photocoagulation jointly in treating severe proliferative diabetic retinopathy(PDR).Methods Totally 120 patients(216 eyes) of PDR treated during the period from Jun.2018 to Aug.2019 were selected and divided randomly into a control group and an observation group,60 patients in each group.The patients in the control group were treated with Conbercept and laser photocoagulation.Laser photocoagulation was performed 1 week before the injection of Conbercept.The laser parameters were set as follows:exposure time 100-150 ms,energy 100-180 mW,photocoagulation intensity Ⅰ~Ⅱ,spot size 100 μm,and spot distance the size of a spot.The patients in the observation group were given Hexuemingmu tablets in addition.The best corrected visual acuity,improvement of retinal exudation,thickness of macular fovea and incidence of adverse reactions were compared between the two groups 1 month、2 months、3 months after the treatment.Results Upon the treatment,the best corrected visual acuity in the observation group was significantly higher than that in control group(P<0.05).While the retinal leakage and thickness of macular fovea being improved in both groups after the treatment,the improvement was more remarkable in the observation group than in the control group(P<0.05).After the treatment,no complication such as endophthalmitis,postoperative bleeding and retinal detachment occurred in either group(P>0.05).Conclusions The combination of Hexuemingmu tablet,Conbercept and retinal photocoagulation will improve patients’ visual therapy and promote their recovery in the treatment of severe PDR.

关 键 词：和血明目片 康柏西普 视网膜光凝 重度PDR 

分 类 号：R616.4[医药卫生—外科学] R774.1[医药卫生—临床医学]